HypGen Inc. to Present During Biotech Showcase 2018
CENTURY CITY, CA , Jan. 05, 2018 (GLOBE NEWSWIRE) -- HypGen Inc. (OTCQB: HPGN), announced it will present during the Biotech Showcase™ 2018, in San Francisco. HypGen is developing the drug RP-323 for the treatment of Parkinson's disease.
HypGen’s CEO, Dr. McCoy L. Moretz, will present at the “Asia Drug Development Networking Event” hosted by CMIC Holdings and CORCEPT 190 on Sunday, January 7, 2018.
A copy of the presentation is available via the Company’s website at www.hypgeninc.com under the Investor’s Section; or by following this link: Download our CMIC Presentation.
About Dr. McCoy L. Moretz
Dr. McCoy L. Moretz is a Board certified surgeon with more than 30 years of experience, and has operated successful private practices in Atlanta, Georgia and California. Board Certified by the ABO, a member of the American Board of Medical Specialties, Fellow of the American College of Surgeons; American Board of Otolaryngology/Head & Neck Surgery; American Academy of Facial Plastic & Reconstructive surgery; American Academy of Cosmetic Surgery; and American Academy of Otolaryngology / Head & Neck Surgery.
About HypGen Inc.
HypGen intends to focus its efforts on developing therapeutics treatment for Parkinson's disease. HypGen has been assigned all of the right, title and interest in United States Utility Patent Application No. 62/420,177 filed on November 10, 2016 (the "Patent Application"), titled "COMPOSITIONS AND METHODS OF USE OF PHORBOL ESTERS FOR THE TREATMENT OF PARKINSON'S DISEASE" and all related intellectual property, inventions and trade secrets, data, and clinical study results. More than 10 million people worldwide are impacted by this disease and the market is estimated at $10 billion.
News 
Market Data 
Discover 
